Literature DB >> 21133741

Legal liability perspectives on abuse-deterrent opioids in the treatment of chronic pain.

David B Brushwood1, Ben A Rich, John J Coleman, Jennifer Bolen, Winston Wong.   

Abstract

Abuse-deterrent opioid analgesic formulations can help reduce the risk of opioid diversion and abuse. Not all opioid analgesics are available as both extended- and immediate-release dosage forms in abuse-deterrent formulations. Clinicians may have to balance the clinical benefit of a product that does not use abuse-deterrent technology versus the regulatory benefit of using a product with this technology. There is the possibility that a health care professional may be held legally liable when a product without abuse-deterrent qualities is used and a person suffers harm that would not have occurred had an abuse-deterrent formulation been provided. This article reviews legal precedents that inform an understanding of the need to reduce malpractice exposure by identifying patients who are at high risk of opioid diversion and/or abuse and considering the use of an abuse-deterrent formulation for these patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21133741     DOI: 10.3109/15360288.2010.524979

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN: 1536-0288


  6 in total

1.  Impact of an Electronic Pain and Opioid Risk Assessment Program: Are There Improvements in Patient Encounters and Clinic Notes?

Authors:  Stephen F Butler; Kevin L Zacharoff; Sadaf Charity; Ryan A Black; Emma Chung; Antje Barreveld; Molly S Clark; Robert N Jamison
Journal:  Pain Med       Date:  2016-04-20       Impact factor: 3.750

Review 2.  Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering.

Authors:  Steven P Stanos; Patricia Bruckenthal; Robert L Barkin
Journal:  Mayo Clin Proc       Date:  2012-07       Impact factor: 7.616

3.  A practical and ethical solution to the opioid scheduling conundrum.

Authors:  Michael E Schatman; Beth D Darnall
Journal:  J Pain Res       Date:  2013-12-06       Impact factor: 3.133

4.  The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability.

Authors:  Michael E Schatman; Lynn R Webster
Journal:  J Pain Res       Date:  2015-03-18       Impact factor: 3.133

5.  Tibia shaft fractures: costly burden of nonunions.

Authors:  Evgeniya Antonova; T Kim Le; Russel Burge; John Mershon
Journal:  BMC Musculoskelet Disord       Date:  2013-01-26       Impact factor: 2.362

6.  Long-term opioid treatment of chronic nonmalignant pain: unproven efficacy and neglected safety?

Authors:  Igor Kissin
Journal:  J Pain Res       Date:  2013-07-04       Impact factor: 3.133

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.